about
Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasmsGUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patientsMechanisms of Weight Regain following Weight LossGuanylyl cyclase C as a biomarker in colorectal cancerGUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrityGuanylyl cyclase C signaling axis and colon cancer preventionExposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceBile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cellsA validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancerGuanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrityCalorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesityAntiobesity pharmacotherapy: new drugs and emerging targetsCurrent trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.Regulation of appetite to treat obesity.Chronic diseases: the emerging pandemic.New advances in models and strategies for developing anti-obesity drugs.Transitioning biomarkers into the clinic.Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.Identification and characterization of a new family of high-affinity receptors for Escherichia coli heat-stable enterotoxin in rat intestinal membranes.Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.Selection of optimal reference genes for normalization in quantitative RT-PCR.Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis.Previstage GCC test for staging patients with colorectal cancer.The roadmap to personalized medicineClinical and translational sciences: at the intersection of molecular and individualized medicine.Clinical and translational science: from bench-bedside to global villageClinical translational science 2020: disruptive innovation redefines the discovery-application enterpriseTranslating colorectal cancer prevention through the guanylyl cyclase C signaling axis.Obesity pharmacotherapy: what is next?Sizing up pharmacotherapy for obesityA conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer.Pharmacokinetics of ertapenem in healthy young volunteers.The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancerPharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease.The pharmacokinetics of taurolidine metabolites in healthy volunteers.Bacterial enterotoxins are associated with resistance to colon cancer.
P50
Q24631234-94129ABF-6226-4477-8A28-8957F992C004Q24641833-FE53427E-3A59-4467-B720-A0DB83192327Q26865399-1A53CFE1-707B-4D54-B1A2-C9A970CB1288Q27011759-030D193E-673A-40CC-AD93-F8CCE8719B34Q27308895-B29970BA-107A-4D12-B984-0FCEF016299AQ28074181-B45338B5-AD8F-4ED0-A76D-C7EB1F0E6AB4Q28204828-E89B7609-152F-458D-8DFC-F7C58364F2DEQ28235080-08B95774-6F7A-4177-A85F-BF5604816B28Q28256902-9553BF26-26FE-4070-A809-23F7BD8AE3E8Q28509565-CB49C764-8C45-4C86-9682-F34316119A3AQ28828838-5175E7D0-7CB4-4B0A-9A39-B6098C00629BQ30354242-B96DBAB3-03A2-40BE-8B12-AC44D83E5C22Q30399390-6115DFB2-8BD3-4AC5-9AC2-312A7BF53DCBQ30403705-7D499F5D-1C77-47CC-B4DE-2F12543A2EFEQ30404279-3D5502F7-6848-4C4A-9E39-1496DE5EF5E5Q30429816-CB0FFDEE-9B62-4A64-96A1-C104E8939207Q30457306-3239D811-C4EF-400D-92E4-C0E6FA94AD9FQ30488671-FB1F1B57-D470-44B8-96F3-D79B726422BCQ30490467-91F8E037-A8FF-4AF2-A813-C79C720D5DCEQ30584571-2A5E043A-09CD-4027-85C8-431A3133D62CQ30815469-8500F6EC-24C1-4884-B320-09D5F5CCA9AEQ31047861-3DE73185-30CA-4830-BC77-15D4044BB399Q33237217-585734DF-82D9-466E-B9EF-FD5AA4B28683Q33578372-B0AEF36A-78C8-471E-A3E7-4EB29536A80EQ33610075-96C538F9-BF2E-4EF6-B6FF-4F17D95F1921Q33641600-57B981EE-555C-43C2-B987-5EFED8FB53EAQ33712658-EB07788A-A45D-41DF-A472-81A7199B1899Q33712718-F06E7F48-8525-442D-900B-D7456D1A6CE0Q33712799-1ED01855-BCC1-444A-B73C-598575055B0AQ33713415-8DD7F884-9EE2-4869-9244-BA831ECC352AQ33722761-565D0366-A438-4735-A6E0-A65C2CCD51D4Q33827988-239B193B-1627-4DA8-86DD-EF774517141DQ33969368-387B2DEC-D9F2-4517-ADA7-F1221C32E9D2Q33999947-91FA17CD-37FC-4069-8B4A-7B93862A8579Q34141850-63F34CF1-3C37-420F-BDE2-BA81B9BB9C50Q34458591-1ED0DE90-E4E4-479C-A8C4-419AA299D04CQ34544822-CFE5EF1C-9BA9-4F8F-9581-DD8EE8B4E9F8Q34555325-B64F4DCD-EB76-40FC-B51D-047797B4E397Q34613916-355FA818-3DD6-490A-9D21-C513E2F1E527Q34808083-67816444-2569-40DE-B1E5-EF8DD9A64565
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Scott A Waldman
@nl
Scott A Waldman
@sl
Scott A. Waldman
@en
Scott A. Waldman
@es
type
label
Scott A Waldman
@nl
Scott A Waldman
@sl
Scott A. Waldman
@en
Scott A. Waldman
@es
altLabel
Scott Waldman
@en
Waldman SA
@en
prefLabel
Scott A Waldman
@nl
Scott A Waldman
@sl
Scott A. Waldman
@en
Scott A. Waldman
@es
P106
P1153
7102179927
P21
P31
P4012
P496
0000-0001-6619-175X